pharvaris nv - PHVS
PHVS
Close Chg Chg %
31.54 0.52 1.65%
Open Market
32.06
+0.52 (1.65%)
Volume: 41.57K
Last Updated:
Oct 27, 2026, 1:12 PM EDT
Company Overview: pharvaris nv - PHVS
PHVS Key Data
| Open $31.62 | Day Range 31.59 - 32.30 |
| 52 Week Range 21.03 - 43.25 | Market Cap $2.19B |
| Shares Outstanding 69.86M | Public Float 33.60M |
| Beta -2.46 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.05 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 661.56K |
PHVS Performance
| 1 Week | 0.41% | ||
| 1 Month | -1.50% | ||
| 3 Months | -7.70% | ||
| 1 Year | 37.19% | ||
| 5 Years | 80.95% |
PHVS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
15
Full Ratings ➔
About pharvaris nv - PHVS
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
PHVS At a Glance
Pharvaris NV
Emmy Noetherweg 2
Leiden, Zuid-Holland 2333 BK
| Phone | 31-71-203-64-10 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -198,290,465.39 | |
| Sector | Health Technology | Employees | 129 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PHVS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.68 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.80 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
PHVS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,537,135.391 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PHVS Liquidity
| Current Ratio | 10.106 |
| Quick Ratio | 10.106 |
| Cash Ratio | 9.853 |
PHVS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -60.476 |
| Return on Equity | -66.556 |
| Return on Total Capital | -62.061 |
| Return on Invested Capital | -66.406 |
PHVS Capital Structure
| Total Debt to Total Equity | 0.286 |
| Total Debt to Total Capital | 0.286 |
| Total Debt to Total Assets | 0.258 |
| Long-Term Debt to Equity | 0.213 |
| Long-Term Debt to Total Capital | 0.212 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Pharvaris Nv - PHVS
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 160.74K | 278.44K | 291.58K | 472.14K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 160.74K | 278.44K | 291.58K | 472.14K | |
Depreciation
| 160.74K | 278.44K | 291.58K | 472.14K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +75.77% | +73.23% | +4.72% | +61.92% | |
Gross Income
| (160.74K) | (278.44K) | (291.58K) | (472.14K) | |
Gross Income Growth
| -75.77% | -73.23% | -4.72% | -61.92% | |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 90.97M | 104.50M | 157.30M | 191.19M | |
Research & Development
| 60.30M | 70.89M | 106.62M | 140.48M | |
Other SG&A
| 30.67M | 33.60M | 50.68M | 50.70M | |
SGA Growth
| +42.37% | +14.86% | +50.53% | +21.54% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (91.13M) | (104.77M) | (157.59M) | (191.66M) | |
Non Operating Income/Expense
| 11.67M | (3.13M) | 14.43M | (4.19M) | |
Non-Operating Interest Income
| - | - | 5.92M | 7.38M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 41.25K | 22.14K | 50.75K | 195.09K | |
Interest Expense Growth
| -86.95% | -46.34% | +129.25% | +284.44% | |
Gross Interest Expense
| 41.25K | 22.14K | 50.75K | 195.09K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (79.51M) | (107.92M) | (143.21M) | (196.05M) | |
Pretax Income Growth
| -57.68% | -35.74% | -32.70% | -36.89% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| 713.70K | 1.13M | 1.97M | 2.24M | |
Income Tax - Current - Domestic
| 796.02K | 512.04K | 1.12M | 1.23M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (82.32K) | 621.84K | 856.60K | 1.02M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (80.22M) | (109.06M) | (145.19M) | (198.29M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (80.22M) | (109.06M) | (145.19M) | (198.29M) | |
Net Income Growth
| -58.84% | -35.94% | -33.13% | -36.58% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (80.22M) | (109.06M) | (145.19M) | (198.29M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (80.22M) | (109.06M) | (145.19M) | (198.29M) | |
EPS (Basic)
| -2.3886 | -2.8407 | -2.6876 | -3.3518 | |
EPS (Basic) Growth
| -43.82% | -18.93% | +5.39% | -24.71% | |
Basic Shares Outstanding
| 33.59M | 38.39M | 54.02M | 59.16M | |
EPS (Diluted)
| -2.3886 | -2.8407 | -2.6876 | -3.3518 | |
EPS (Diluted) Growth
| -43.82% | -18.93% | +5.39% | -24.71% | |
Diluted Shares Outstanding
| 33.59M | 38.39M | 54.02M | 59.16M | |
EBITDA
| (90.97M) | (104.50M) | (157.30M) | (191.19M) | |
EBITDA Growth
| -42.37% | -14.86% | -50.53% | -21.54% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 51.156 | |
| Number of Ratings | 15 | Current Quarters Estimate | -0.771 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -2.796 | |
| Last Quarter’s Earnings | -0.715 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.97 | Next Fiscal Year Estimate | -2.708 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 7 | 13 | 13 |
| Mean Estimate | -0.77 | -0.79 | -2.80 | -2.71 |
| High Estimates | -0.66 | -0.66 | -2.39 | -2.11 |
| Low Estimate | -0.90 | -0.96 | -3.01 | -3.52 |
| Coefficient of Variance | -10.21 | -13.22 | -5.86 | -16.98 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 15 | 14 | 14 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Pharvaris Nv - PHVS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Pharvaris Nv - PHVS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 14, 2026 | Peng Lu President | 110,152 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.1 per share | 3,425,727.20 |
| Oct 14, 2026 | Peng Lu President | 110,035 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.1 per share | 3,422,088.50 |
| Sep 18, 2026 | Stefan Abele Chief Technical Ops Officer | 85,468 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.4 per share | 1,401,675.20 |
| Sep 18, 2026 | Stefan Abele Chief Technical Ops Officer | 40,468 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.14 per share | 1,543,449.52 |
| Sep 18, 2026 | Stefan Abele Chief Technical Ops Officer | 39,068 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $39.24 per share | 1,533,028.32 |
| Sep 18, 2026 | Stefan Abele Chief Technical Ops Officer | 44,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 16, 2026 | Berndt A. E. Modig Chief Executive Officer; Director | 128,334 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $39.4 per share | 5,056,359.60 |
| Sep 16, 2026 | Peng Lu President | 65,070 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $37.51 per share | 2,440,775.70 |
| Sep 16, 2026 | Peng Lu President | 64,953 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $38.02 per share | 2,469,513.06 |
| Sep 15, 2026 | Anne Lesage Chief Early Development | 86,450 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8.05 per share | 695,922.50 |
| Sep 15, 2026 | Anne Lesage Chief Early Development | 56,450 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.3 per share | 2,162,035.00 |
| Sep 15, 2026 | Anne Lesage Chief Early Development | 15,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2026 | Peng Lu Chief Medical Officer | 205,308 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 9, 2026 | Anna Nijdam Principal Accounting Officer | 49,488 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.56 per share | 1,413,377.28 |